Karagiannakis Dimitrios S, Stefanaki Katerina, Paschou Stavroula A, Papatheodoridi Margarita, Tsiodras Sotirios, Papanas Nikolaos
Academic Department of Gastroenterology, Laiko General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Endocrine Unit and Diabetes Center, Department of Clinical Therapeutics, School of Medicine, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Hormones (Athens). 2024 Dec 19. doi: 10.1007/s42000-024-00625-z.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of end-stage liver disease and liver transplantation in the Western world, with an approximate prevalence of 30% worldwide which is continuously rising. It is characterized by intrahepatic fat deposition along with at least one cardiometabolic risk factor, such as diabetes mellitus, obesity, hypertriglyceridemia, and hypertension. MASLD consists of a spectrum of liver diseases ranging from simple liver steatosis to steatohepatitis, liver fibrosis, and cirrhosis. Recently, the European Association for the Study of the Liver (EASL), the European Association for the Study of Diabetes (EASD), and the European Association for the Study of Obesity (EASO) released the latest guidelines regarding the management of patients with MASLD. This article highlights the critical points of these guidelines and emphasizes problematic issues that need further evaluation.
代谢功能障碍相关脂肪性肝病（MASLD）是西方世界终末期肝病和肝移植的主要原因，在全球的患病率约为30%，且呈持续上升趋势。其特征是肝内脂肪沉积以及至少一种心血管代谢危险因素，如糖尿病、肥胖、高甘油三酯血症和高血压。MASLD包括一系列肝脏疾病，从单纯性肝脂肪变性到脂肪性肝炎、肝纤维化和肝硬化。最近，欧洲肝脏研究协会（EASL）、欧洲糖尿病研究协会（EASD）和欧洲肥胖研究协会（EASO）发布了关于MASLD患者管理的最新指南。本文重点介绍了这些指南的关键点，并强调了需要进一步评估的问题。
